Recent 8-K filings for GPCR

• May 7, 2026, 7:59 PM ET other material materiality 0.90 positive item 1.01item 2.02item 8.01item 9.01 ◈ Earnings Releases◈ Material Agreements

  Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials

  Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.

• April 15, 2026, 7:59 PM ET leadership materiality 0.65 positive item 5.02item 7.01item 9.01

  Structure Therapeutics appoints Matthew Lang as COO and General Counsel

  Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.

• March 16, 2026, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks

  Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.

• February 26, 2026, 6:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2

  Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.

• January 5, 2026, 6:59 PM ET other material materiality 0.85 positive item 1.01 ◈ Material Agreements

  Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront

  Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.

• December 10, 2025, 6:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Structure Therapeutics launches $650M follow-on offering of ADSs and pre-funded warrants

  Gross proceeds ~$650M from 8.46M ADSs at $65.00 and 1.54M pre-funded warrants at $64.9999.

• December 8, 2025, 6:59 PM ET other material materiality 0.90 positive item 7.01item 8.01item 9.01

  Structure Therapeutics reports positive Phase 2 data for oral GLP-1 aleniglipron; plans Phase 3 by mid-2026

  Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg in Phase 2b ACCESS study; up to 15.3% (35.5 lbs) at 240 mg in exploratory ACCESS II.

• November 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025

  Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.

• August 6, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Structure Therapeutics reports Q2 net loss $61.7M; cash $786.5M; aleniglipron data on track for year-end 2025

  Net loss $61.7M vs $26.0M YoY; R&D expenses $54.7M (up from $22.1M) due to advancing GLP-1 program.

• June 25, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Structure Therapeutics shareholders elect directors, ratify auditor at 2025 AGM

  Eric Dobmeier and Joanne Waldstreicher elected as Class II directors (133.7M and 131.4M votes for).

• May 8, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Structure Therapeutics Q1 net loss $46.8M; cash $836.9M; aleniglipron Ph2b data expected by year-end

  Net loss of $46.8M in Q1 2025 vs $26.0M in Q1 2024; R&D expenses $42.9M (up from $20.7M).

• February 27, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Structure Therapeutics: aleniglipron studies fully enrolled; Q4 net loss $36.5M, cash $883.5M

  ACCESS and ACCESS II studies fully enrolled on schedule; topline 36-week data expected by year-end 2025.

• December 17, 2024, 6:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025

  ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.

• November 13, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Structure Therapeutics reports Q3 2024 net loss of $34M; first patients dosed in Phase 2b ACCESS obesity study

  Cash, cash equivalents and short-term investments $915.3M; expected to fund operations through at least 2027 excluding Phase 3 registrational studies.

• September 17, 2024, 7:59 PM ET leadership materiality 0.70 neutral item 5.02item 7.01item 8.01item 9.01 ◈ executive_change

  Structure Therapeutics appoints Blai Coll as CMO, Ashley Hall as CDO; Mark Bach departs in planned succession

  Mark Bach to depart as CMO effective Sept 18; will serve as advisor through Dec 31.

• August 27, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Structure Therapeutics appoints Angus Russell to Board, Audit Committee

  Angus Russell appointed Class I director effective Aug 26, 2024; term expires at 2027 annual meeting.

• August 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Structure Therapeutics Q2 net loss $26M; cash $927M; GSBR-1290 Phase 2b on track Q4 2024

  Q2 2024 net loss $26.0M vs $23.3M in Q2 2023; R&D expenses $22.1M, G&A $11.3M.

• June 27, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 8.01

  Structure Therapeutics elects Sharon Tetlow to board; Ted Love joins audit committee

  Sharon Tetlow elected as Class I director for 3-year term with 117.2M votes for, 12.6M against.

• June 3, 2024, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290

  GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.

• June 3, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Structure Therapeutics updates risk factors and GLP-1 agonist market data in 8-K filing

  Updated disclosure: six GLP-1R agonists generated ~$35.9B in 2023 sales, projected to reach $85.9B by 2027.

• May 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024

  Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.

• March 8, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024

  Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

9 positive 0 negative 13 neutral

source · GPCR on sec.gov